Login
Navigate Fool.com
Will MNKD beat
the market?

MannKind Corp

NASDAQ: MNKD

Community Rating: 2 Stars: Unattractive

6.25 -0.14 (-2.19%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.34
Previous Close $6.39
Daily Range $6.22 - $6.46
52-Week Range $3.72 - $8.70
Market Cap $2.4B
P/E Ratio -9.77
Dividend (Yield) $0.00 (0.0%)
Volume 4,423,794
Average Daily Volume 14,400,233
Current FY EPS -$0.31

How do you think MNKD
will perform against the market?

Top MNKD Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted January 27, 2011

So ... tired ... of ... talking ... about ... MannKind ... There's still lots of KoolAid left in the jug.

6 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted December 22, 2010

There's no point in going over what's been argued a million times. At this price level, I see more downside in the short-term regardless of the PDUFA outcome. I think another technical CRL is the most … More

6 Replies Reply Report this Post

News & Commentary Rss Feed

5 Unlikely Companies Bucking the Biotech Sell-Off

The SPDR S&P Biotech ETF is down 22.4% over the trailing month, but these five biotech stocks are all up. What's their secret?

XBI, MNKD, UTHR, ARNA: Large Inflows Detected at ETF

Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)

The market cap of Galena Biopharma, Sangamo BioSciences, and ANI Pharmaceuticals, and MannKind is more important than the share price.

MannKind's Overly-Optimisitic Investors

Despite issues, over half of investors in a Motley Fool poll thought MannKind's inhaled insulin, Afrezza, would be approved this week.

This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere

A surprise buyout, MannKind's sanguine PDUFA update regarding Afrezza, and three positive clinical studies, mark this week's top biotech stories.

MannKind vs. Idenix: Better Biotech Buy

What's the better buy in biotech today?

Closing Update: Wall Street Extends Losing Streak On Worries Over Earnings, Valuation

Mid-Afternoon Market Update: Markets Continue to Show Weakness as Defensive Names Come into Favor

Why MannKind Corp. Shares Made One Giant Leap Downward

MannKind shares get pummeled after the company updates its marketing application status for Afrezza.

FDA Keeps Driving Up Future Cost of Inhalable Insulin

See More MNKD News...

Sector

Healthcare

Industry

Drugs

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website: http://www.mannkindcorp.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks